The global autoimmune disease diagnostics market size was valued at USD 6.78 billion in 2025 and is projected to grow from USD 7.29 billion in 2026 to USD 13.02 billion by 2034, registering a CAGR of 7.52% during the forecast period from 2026 to 2034. North America dominated the autoimmune disease diagnostics market with a market share of 39.5% in 2025.
The autoimmune disease diagnostic market is expanding steadily as the prevalence of autoimmune disorders such as rheumatoid arthritis, lupus, and multiple sclerosis rises worldwide. Increased awareness among healthcare providers and patients about early detection fuels demand for precise diagnostic tools. In October 2025, Abbott received FDA clearance for a new multiplex autoimmune panel detecting 12 autoantibodies simultaneously, improving diagnostic breadth and efficiency.
Advancements in fully automated immunoassay analyzers and AI‑assisted interpretation tools enhance sensitivity and reduce misdiagnosis. Strategic collaborations between diagnostic companies and research institutions strengthen R&D, while emerging AI‑based models help analyze complex immune signatures. Expansion of healthcare infrastructure in emerging regions and public health initiatives promoting autoimmune screening further support growth. However, challenges like high test costs and limited insurance coverage slow adoption, highlighting the need for a rapid diagnostics solution.
Download a Free Sample To learn more about this report,
Increasing Adoption of Multiplex Autoantibody and Biomarker-Based Testing
Autoimmune disease diagnostics are increasingly moving toward multiplex platforms that can evaluate multiple autoantibodies and disease-related biomarkers from a single patient sample. These technologies can improve diagnostic efficiency, support differential diagnosis across conditions with overlapping symptoms, and provide broader clinical information for disease characterization and monitoring.
Growing Integration of Laboratory Automation and Artificial Intelligence in Autoimmune Diagnostics
Clinical laboratories are increasingly integrating automated immunoassay platforms, digital analysis, and artificial intelligence into autoimmune testing workflows. Automation can improve testing throughput and consistency, while advanced analytics can support interpretation of complex antibody patterns and help clinicians identify disease signals more efficiently.
Rising Prevalence of Autoimmune Disorders and Demand for Earlier Diagnosis Support Market Growth
The growing burden of autoimmune disorders is increasing demand for diagnostic technologies capable of detecting disease-associated antibodies and biomarkers at earlier stages. Earlier and more accurate diagnosis can help reduce prolonged diagnostic pathways, support timely treatment decisions, and improve monitoring of patients with chronic autoimmune conditions.
Diagnostic Complexity and Limited Disease-Specific Biomarkers Can Limit Testing Efficiency
Many autoimmune disorders share similar clinical manifestations and lack a single highly specific diagnostic marker. Healthcare professionals may therefore need to combine autoantibody testing, inflammatory markers, imaging, pathology, and clinical assessment, increasing testing requirements and potentially extending the time and cost associated with establishing an accurate diagnosis.
Expansion of Autoimmune Diagnostic Services Across Emerging Healthcare Markets Creates New Growth Opportunities
Growing healthcare infrastructure and improving access to laboratory services in emerging markets are creating opportunities to expand autoimmune disease testing beyond established diagnostic centers. Investments in clinical laboratories, diagnostic equipment, specialist healthcare services, and decentralized testing capabilities can improve access to autoimmune screening and monitoring while broadening the geographic reach of diagnostic providers.
Maintaining Diagnostic Accuracy, Standardization, and Regulatory Compliance Creates Challenges
Autoimmune diagnostic platforms must deliver consistent results across different laboratories, assay technologies, patient populations, and specimen conditions. Variability in testing methods, interpretation of antibody patterns, regulatory requirements, and validation standards can create challenges for laboratories and manufacturers seeking reliable and comparable diagnostic results across healthcare systems.
Assay Kits & Consumables Segment is Projected to Register the Fastest Growth at a CAGR of 9.2%
The assay kits & consumables segment is projected to register the fastest growth at a CAGR of 9.2% during 2026–2034. In 2025, the segment accounted for 65.8% of the global autoimmune disease diagnostic market, with a value of USD 4.46 billion. Growth is driven by increasing demand for reliable autoimmune disease testing, rising diagnostic volumes, and the expanding use of specialized assay kits for detecting disease-specific biomarkers and autoantibodies. Growing emphasis on early diagnosis and disease monitoring continues to support the segment's growth.
The instruments segment continues to maintain a significant market presence owing to the increasing adoption of automated diagnostic platforms and laboratory testing systems. Rising investments in laboratory infrastructure and growing demand for high-throughput testing capabilities continue to support the use of advanced diagnostic instruments.
Increasing automation across diagnostic laboratories is also contributing to demand for integrated instruments and consumable-based testing workflows. Improvements in assay performance and laboratory efficiency are expected to further support adoption across healthcare settings.
Request Customizationto receive a tailored report.
Inflammatory Bowel Disease Segment is Projected to Register the Fastest Growth at a CAGR of 9.4%
The inflammatory bowel disease segment is projected to register the fastest growth at a CAGR of 9.4% during 2026–2034. In 2025, the segment accounted for 13.5% of the global autoimmune disease diagnostic market, with a value of USD 0.92 billion. Growth is driven by increasing prevalence of inflammatory bowel conditions, rising awareness of early diagnosis, and growing demand for accurate disease monitoring. Advances in biomarker-based testing and improved diagnostic approaches continue to support the segment's growth.
Rheumatoid arthritis dominated the market owing to its substantial patient population and the widespread use of diagnostic testing for disease identification and monitoring. Systemic lupus erythematosus, type 1 diabetes, and autoimmune thyroid diseases continue to witness steady demand as awareness of autoimmune disorders increases and healthcare providers place greater emphasis on early detection.
Scleroderma and vasculitis contribute to market growth through demand for specialized diagnostic testing, while other diseases continue to support the market through testing requirements associated with a broad range of autoimmune conditions.
Point-of-Care Testing Segment is Projected to Register the Fastest Growth at a CAGR of 10.1%
The point-of-care testing segment is projected to register the fastest growth at a CAGR of 10.1% during 2026–2034. In 2025, the segment accounted for 9.4% of the global autoimmune disease diagnostic market, with a value of USD 0.64 billion. Growth is driven by increasing demand for rapid diagnostic results, decentralized testing, improved accessibility, and faster clinical decision-making. Growing adoption of convenient diagnostic technologies continues to support the segment's growth.
Immunoassays dominated the market owing to their broad application in detecting autoantibodies and other disease-related biomarkers. Indirect immunofluorescence continues to play an important role in autoimmune disease diagnosis, while multiplex assays are gaining demand because they enable the simultaneous assessment of multiple biomarkers.
Molecular diagnostics continues to expand through advances in biomarker detection and molecular testing capabilities, while other technologies contribute to the market by supporting specialized diagnostic applications across autoimmune disease testing.
Clinical Laboratories Segment is Projected to Register the Fastest Growth at a CAGR of 9.1%
The clinical laboratories segment is projected to register the fastest growth at a CAGR of 9.1% during 2026–2034. In 2025, the segment accounted for 42.8% of the global autoimmune disease diagnostic market, with a value of USD 2.90 billion. Growth is driven by increasing demand for specialized autoimmune testing, rising diagnostic volumes, and the growing use of advanced laboratory technologies. Increasing outsourcing of diagnostic testing and improvements in laboratory infrastructure continue to support the segment's growth.
Hospitals & clinics accounted for a substantial portion of the market owing to their role in diagnosing and managing patients with autoimmune disorders. Increasing patient visits, growing availability of specialized diagnostic services, and the need for disease monitoring continue to support demand across these healthcare settings.
Academic & research institutes continue to contribute to market development through autoimmune disease research, biomarker discovery, and evaluation of emerging diagnostic technologies. Other end users also support demand through specialized testing and healthcare applications.
Speak to an Analystto discuss market opportunities.
North America autoimmune disease diagnostic market accounted for 39.5% of the global market, reaching USD 2.68 billion in 2025, and is projected to grow at a CAGR of 8.2% during the forecast period. The market is driven by the increasing prevalence of autoimmune disorders, growing demand for early and accurate diagnosis, rising healthcare expenditure, and expanding adoption of advanced immunoassay and molecular diagnostic technologies. Increasing awareness of autoimmune diseases and continuous advancements in diagnostic testing continue to support regional market growth.
The US market was valued at USD 2.28 billion in 2025, making it the largest contributor in North America. Increasing prevalence of autoimmune disorders, growing adoption of advanced diagnostic technologies, rising healthcare investments, and increasing demand for early disease detection continue to drive market growth.
Canada's market reached USD 0.40 billion in 2025. Growing awareness of autoimmune diseases, increasing healthcare expenditure, expanding access to diagnostic services, and rising adoption of advanced laboratory testing technologies continue to support steady market expansion.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe autoimmune disease diagnostic market accounted for 28.4% of the global market, reaching USD 1.93 billion in 2025, and is projected to grow at a CAGR of 7.9% during the forecast period. Rising prevalence of autoimmune diseases, increasing focus on early diagnosis, expanding healthcare infrastructure, and growing adoption of advanced diagnostic technologies continue to strengthen regional market growth. Increasing investments in laboratory automation and personalized healthcare further support market expansion.
The UK market was valued at USD 0.39 billion in 2025. Increasing demand for accurate autoimmune disease testing, expanding healthcare screening initiatives, growing adoption of advanced immunodiagnostic technologies, and rising investments in healthcare services continue to support market growth.
Germany market accounted for USD 0.54 billion in 2025. Strong healthcare infrastructure, increasing prevalence of autoimmune disorders, growing adoption of laboratory automation, and rising investments in advanced diagnostic technologies continue to drive market expansion.
Asia Pacific autoimmune disease diagnostic market accounted for 22.6% of the global market, reaching USD 1.53 billion in 2025, and is projected to grow at a CAGR of 10.6% during the forecast period. Increasing prevalence and awareness of autoimmune disorders, rapid healthcare infrastructure development, growing healthcare expenditure, and rising adoption of advanced diagnostic technologies continue to accelerate regional market growth. Expanding access to specialized diagnostic services further strengthens market expansion.
China's market accounted for USD 0.64 billion in 2025, representing the largest share within Asia Pacific. Expanding healthcare infrastructure, increasing awareness of autoimmune diseases, growing adoption of advanced laboratory diagnostics, and rising investments in healthcare technologies continue to drive market expansion.
Japan's market generated USD 0.28 billion in 2025. Increasing demand for early autoimmune disease detection, growing elderly population, expanding adoption of advanced diagnostic systems, and rising healthcare modernization continue to support market growth.
Middle East and Africa autoimmune disease diagnostic market accounted for 3.8% of the global market, totaling USD 0.26 billion in 2025, and is projected to grow at a CAGR of 7.6% during the forecast period. Increasing investments in healthcare infrastructure, growing awareness of autoimmune diseases, expanding access to diagnostic services, and rising adoption of advanced laboratory technologies continue to support regional market growth.
The UAE market was valued at USD 0.07 billion in 2025. Increasing investments in advanced healthcare facilities, expanding adoption of specialized diagnostic technologies, growing medical tourism, and rising focus on early disease detection continue to drive market growth.
Africa's market reached USD 0.19 billion in 2025. Expanding healthcare access, increasing investments in diagnostic infrastructure, growing awareness of autoimmune disorders, and rising demand for affordable and accurate diagnostic solutions continue to create long-term growth opportunities across the region.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
CRISPR Gene Editing Market Size, Share, Growth, Analysis, 2034
Mass Spectrometry Market Size, Share, Growth, Analysis, 2034
Blood Testing Market Size, Share, Growth, Analysis, Report, 2034
3D Cell Culture Market Size, Share, Growth, Analysis, Report, 2034
3D Bioprinting Market Size, Share, Growth, Analysis, Report, 2034
United Kingdom Epigenetics Market Size, Trends, Top Share and Forecast to 2034
We are featured on:
sales@straitsresearch.com